What Happens When America Eats Less? Measuring the Economic Ripple Effects of GLP-1 Medications
GLP-1 medications have quickly become one of the biggest disruptors in healthcare. Originally developed to treat diabetes and now widely used for weight management, these medications are changing more than individual health outcomes. As millions of Americans adjust their eating habits and healthcare spending, the effects are beginning to ripple across the broader economy.
Using IMPLAN’s Input-Output model, we analyzed what could happen if GLP-1 adoption expanded to reflect today’s U.S. obesity rate. The results show a major shift in where consumer dollars are spent, creating new opportunities for some industries while challenging others.
A Boom That Extends Beyond Healthcare
To assess the broader economic implications, IMPLAN modeled two concurrent changes among households with annual incomes exceeding $70,000: increased expenditures on GLP-1 pharmaceuticals and decreased spending on food commodities, based on observed consumption patterns among GLP-1 users.
Although reduced food spending negatively affects agriculture and food-related industries, these losses are more than compensated by increased demand for pharmaceuticals. If GLP-1 usage were to expand to the current U.S. obesity rate, the model estimates support for 304,549 jobs, $24.86 billion in labor income, over $82 billion in economic output, and more than $52 billion in GDP.
The most significant gains are observed in industries closely associated with healthcare, such as health and personal care retail, pharmaceutical manufacturing, and real estate. Conversely, sectors related to food production and distribution experience the greatest challenges, particularly food and beverage retailers, beef cattle ranching, and grocery wholesalers.
Healthcare-related industries generate over $82 billion in additional economic output, whereas agricultural, food processing, and food retail industries collectively incur approximately $8.4 billion in output losses. Instead of diminishing overall economic activity, GLP-1 adoption reallocates spending toward healthcare, resulting in a net positive impact and reshaping segments of the food economy.
The Environmental Story Is Just as Significant
Reduced food consumption affects not only business activity but also environmental outcomes.
IMPLAN estimates that lower demand for food commodities could reduce greenhouse gas emissions by 49 million kilograms from beef cattle ranching, 26 million kilograms from dairy cattle and milk production, and more than 215 million kilograms across other agricultural and food processing industries.
These findings illustrate that changes in consumer behavior can yield measurable environmental benefits in addition to broader economic impacts, highlighting the interconnectedness of healthcare, agriculture, and sustainability.
A New Mix of Jobs
As consumer spending transitions from food to pharmaceuticals, corresponding shifts in employment occur.
Healthcare-related occupations and retail sales workers are projected to benefit from increased pharmaceutical demand. Retail sales workers could realize more than $32,000 in wage and salary employment, while healthcare technicians and diagnostic professionals may experience gains ranging from $18,240 to $30,296.
Simultaneously, occupations associated with food production are expected to experience modest declines. Food processing workers and agricultural workers are projected to see reductions in wage and salary employment of $1,631 and $1,305, respectively, as demand decreases across segments of the food supply chain.
Although the overall economic impact of expanded GLP-1 usage is positive, the findings emphasize that economic growth does not benefit all industries or occupations equally. As consumer spending patterns evolve, the composition of the workforce also changes, generating new opportunities in some sectors and challenges in others.
What Comes Next?
The rapid expansion of GLP-1 medications constitutes more than a healthcare trend. This development demonstrates how a single innovation can transform supply chains, consumer spending, labor markets, and environmental outcomes.
Although the reduction in food spending is smaller in magnitude than the gains generated by increased pharmaceutical demand, both shifts significantly affect industries and workers. Food production, agriculture, and related supply chains are likely to experience the most substantial disruption as consumer behavior evolves.
Several important questions remain unresolved. The long-term economic effects will depend on factors such as the duration of patient use of GLP-1 medications and the persistence of changes in food spending. As adoption continues to increase, understanding these ripple effects will become increasingly important for businesses, policymakers, and economic developers.
Measure the Ripple Effects with IMPLAN
Economic change seldom occurs in isolation. Whether evaluating innovations in healthcare, shifts in consumer behavior, or disruptions across entire industries, IMPLAN provides tools to quantify ripple effects across employment, labor income, GDP, supply chains, and environmental impacts.
Want to understand how emerging trends could impact your organization, industry, or region? Schedule a demo to see how IMPLAN helps you measure complex economic changes with confidence.
